Details for Patent: 6,967,208

« Back to Dashboard

Which drugs does patent 6,967,208 protect, and when does it expire?

Patent 6,967,208 protects ELIQUIS SPRINKLE and ELIQUIS and is included in two NDAs.

Protection for ELIQUIS SPRINKLE has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has seventy-four patent family members in thirty-six countries.

Summary for Patent: 6,967,208

Title:	Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
Abstract:	The present application describes lactam-containing compounds and derivatives thereof of Formula I: or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
Inventor(s):	Donald J. P. Pinto, Mimi L. Quan, Michael J. Orwat, Yun-Long Li, Wei Han, Jennifer X. Qiao, Patrick Y. S. Lam, Stephanie L. Koch
Assignee:	Bristol Myers Squibb Co
Application Number:	US10/245,122
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,967,208
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 6,967,208

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bristol	ELIQUIS SPRINKLE	apixaban	FOR SUSPENSION;ORAL	220073-001	Apr 17, 2025		RX	Yes	Yes					Y
Bristol Myers Squibb	ELIQUIS	apixaban	TABLET, FOR SUSPENSION;ORAL	202155-003	Apr 17, 2025		RX	Yes	Yes					Y
Bristol Myers Squibb	ELIQUIS	apixaban	TABLET;ORAL	202155-001	Dec 28, 2012	AB	RX	Yes	No					Y
Bristol Myers Squibb	ELIQUIS	apixaban	TABLET;ORAL	202155-002	Dec 28, 2012	AB	RX	Yes	Yes					Y

International Family Members for US Patent 6,967,208

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1427415		C300500	Netherlands
European Patent Office	1427415		C20110017 00045	Estonia
European Patent Office	1427415		CA 2011 00028	Denmark
European Patent Office	1427415		91888	Luxembourg
European Patent Office	1427415		1190029-7	Sweden
European Patent Office	1427415		PA2011012	Lithuania